Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2009

View Archived Issues

Additive antitumor activity seen with oncolytic measles virus and bevacizumab in glioma model

Schering-Plough presents novel gamma-secretase modulators for Alzheimer's disease

Shionogi presents NPY Y5 receptor antagonists for the treatment of obesity

(R)-Gossypol is safe and well tolerated in glioblastoma and lymphoma patients in phase II trials

ASCO snapshots: Agents investigated in leukemia, myelodysplasia

MKC-1 shows limited activity in platinum-resistant ovarian cancer

Mixed results seen with depsipeptide in radioiodine-refractory thyroid cancer

Schering-Plough discloses kinesin spindle protein inhibitors for cancer treatment

Nerviano Medical Sciences claims Aurora B kinase inhibitors for the treatment of cancer

Abbott describes vanilloid TRPV1 receptor antagonists for the treatment of pain

Oral L-arginine or L-citrulline improves endothelial dysfunction in heart failure outpatients

EMEA provides information on possible interaction between clopidogrel and PPIs

Lundbeck and Takeda report mixed results from phase III trials of Lu AA-21004 in MDD

Centocor signs 5-year CRADA with NCI to develop novel cell therapies to treat cancer

Elite and Epic have announced initial closing under March 2009 strategic alliance agreement

Johnson & Johnson initiates cash tender offer to acquire Cougar Biotechnology

Progenics discontinues development for PRO-206 in hepatitis C

StemCells reports phase I results for HuCNS-SC cells in Batten disease

FDA accepts for review Dyax's complete response submission for DX-88 in HAE

Kuros completes recruitment in phase IIb Kur-111 trial in tibial plateau fractures

Active Biotech completes enrollment in phase II TASQ study

Metabasis receives development event payment from Roche for MB-11362

PanGenetics receives approval for phase I anti-NGF antibody trial in chronic pain

Sinovac commences production of influenza A vaccine

CSL and Talecris mutually agree to terminate August 2008 merger agreement

Alder and Schering-Plough expand collaborative alliance agreement in monoclonal antibodies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...